At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 20 enrolled
Drug / intervention
BI 1358894 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Randomised, Two-way Cross-over, Single-dose, Placebo-controlled Trial to Investigate the Effects of BI 1358894 on Cholecystokinin Tetrapeptide (CCK-4) Induced Panic Symptoms in Healthy Male Subjects
In Brief
A Phase 1 clinical trial evaluating BI 1358894 and Placebo for Healthy. Completed, enrolled 20 participants across 1 site.
Detailed Summary
The main objective of this trial is to investigate the pharmacodynamic effects of a single dose of BI 1358894 on CCK-4- induced anxiogenic/ panic-like symptoms using the PSS in preselected CCK-4 sensitive healthy volunteers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesNetherlands
Collaborators--
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
First PostedApr 2019
Enrollment StartApr 2019
Primary CompletionAug 2019
TodayJul 2026
First PostedApr 5, 2019
Enrollment StartApr 18, 2019
Primary CompletionAug 29, 2019
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 7.2 years ago
Interventions
BI 1358894drug
Film-coated tablet
Placebodrug
Film-coated tablet